Company Encyclopedia
View More
name
Urogen Pharma
URGN.US
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC).
1.945 T
URGN.USMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking104/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE366.31%A
    • Profit Margin-170.59%E
    • Gross Margin88.07%A
  • Growth ScoreC
    • Revenue YoY8.00%B
    • Net Profit YoY-42.70%D
    • Total Assets YoY-38.71%E
    • Net Assets YoY-552.31%E
  • Cash ScoreC
    • Cash Flow Margin-58.62%D
    • OCF YoY8.00%B
  • Operating ScoreC
    • Turnover0.4C
  • Debt ScoreE
    • Gearing Ratio162.37%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    UroGen Pharma Grants Inducement RSUs to 14 New Employees

    UroGen Pharma Ltd. has granted inducement restricted stock units (RSUs) to 14 new employees, with up to 32,500 ordinary shares issuable upon vesting. The RSUs will vest equally over three years, contingent on continued employment. This announcement was published via GlobeNewswire on December 05, 2025.

    Reuters·
    US
    URGN
    -3.07%
    Reuters·
    US
    URGN
    -3.07%

    UroGen Pharma to Present at Piper Sandler Annual Healthcare Conference

    UroGen Pharma Ltd. will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York, NY. The event will include a fireside chat and a webcast available on the company’s Investor Relations website.

    Reuters·
    US
    URGN
    -3.07%
    Reuters·
    US
    URGN
    -3.07%

    UroGen Pharma Chief Medical Officer Mark Schoenberg Sells Common Shares

    Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd., has sold common shares of the company. This event was reported via EDGAR by UroGen Pharma Ltd. on November 20, 2025. The information is for informational purposes and not financial advice.

    Reuters·
    US
    URGN
    -3.07%
    Reuters·
    US
    URGN
    -3.07%

    Officer Schoenberg Sells 10,000 ($250K) Of UroGen Pharma Ltd [URGN]

    Schoenberg Mark Officer of UroGen Pharma Ltd [URGN] filed a Form 4 on November 20, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/19/25TransactionPlanned Sale(1) Shares10,000Price$25.00Value$250,000Ending Holdings: 139,025 - Direct(1) Executed pursuant to a prearranged trading plan (10b5-1).For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    URGN
    -3.07%
    Reuters·
    US
    URGN
    -3.07%

    Officer Schoenberg Files To Sell 10,000 Of UroGen Pharma Ltd [URGN]

    Officer Mark Schoenberg of UroGen Pharma Ltd filed a Form 144 with the SEC to sell 10,000 restricted shares on November 19, 2025, through RBC Capital Markets under a prearranged trading plan (10b5-1).

    Reuters·
    US
    URGN
    -3.07%
    Reuters·
    US
    URGN
    -3.07%
    © 2025 Longbridge｜Disclaimer